TNFAIP2 and prostate adenocarcinoma: In contrast, TNFAIP2 were downregulated in KICH, adrenocortical carcinoma (ACC), pheochromocytoma and paraganglioma (PCPG), prostate adenocarcinoma (PRAD), lung adenocarcinoma (LUAD), rectum adenocarcinoma (READ), lung squamous cell carcinoma (LUSC), skin cutaneous melanoma (SKCM), colon adenocarcinoma (COAD), testicular germ cell tumor (TGCT), thyroid carcinoma (THCA), breast invasive carcinoma (BRCA), esophageal carcinoma (ESCA) and LGG.